VSTM Verastem Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VSTM

Price (delayed)

$6.67

Market cap

$604.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.36

Enterprise value

$551.79M

?
Relative Growth: Rel. Growth: 77
Relative Strength: Rel. Strength: 55
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 19

Verastem Oncology is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in ...

Highlights
VSTM's gross profit has surged by 83% since the previous quarter
VSTM's revenue has surged by 77% since the previous quarter
Verastem's equity has decreased by 39% QoQ but it has increased by 39% YoY
Verastem's quick ratio has decreased by 36% YoY and by 26% from the previous quarter
VSTM's net income is down by 22% year-on-year and by 4.5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.verastem.com
Peers: PFE CRIS LH

Key stats

What are the main financial stats of VSTM

VSTM stock price

How has the Verastem stock price performed over time
Intraday
-4.03%
1 week
12.86%
1 month
24.21%
1 year
-16.83%
YTD
-13.6%
QTD
74.61%

Financial performance

How have Verastem's revenue and profit performed over time
Revenue
$87.53M
Gross profit
$75.58M
Operating income
-$159.96M
Net income
-$202.7M
Gross margin
86.4%
Net margin
-231.6%
Verastem's operating margin has soared by 98% YoY and by 47% from the previous quarter
Verastem's net margin has soared by 97% YoY and by 41% from the previous quarter
VSTM's gross profit has surged by 83% since the previous quarter
VSTM's revenue has surged by 77% since the previous quarter

Price vs fundamentals

How does VSTM's price correlate with its fundamentals

Growth

What is Verastem's growth rate over time

Valuation

What is Verastem stock price valuation
P/E
N/A
P/B
11.73
P/S
7.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.3
Verastem's EPS has increased by 33% YoY
The stock's P/B is 130% above its 5-year quarterly average of 5.1
Verastem's equity has decreased by 39% QoQ but it has increased by 39% YoY
VSTM's revenue has surged by 77% since the previous quarter
The price to sales (P/S) is 62% lower than the last 4 quarters average of 20.1

Efficiency

How efficient is Verastem business performance
Verastem's return on sales has surged by 97% YoY and by 41% QoQ
The ROA has grown by 21% YoY but it has contracted by 3.2% from the previous quarter
The ROIC has grown by 17% YoY
Verastem's return on equity has increased by 3.9% QoQ

Dividends

What is VSTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VSTM.

Financial health

How did Verastem financials performed over time
The total assets is 32% greater than the total liabilities
Verastem's quick ratio has decreased by 36% YoY and by 26% from the previous quarter
The company's current ratio fell by 35% YoY and by 26% QoQ
Verastem's debt is 69% more than its equity
VSTM's debt to equity has surged by 61% since the previous quarter but it is down by 28% year-on-year
Verastem's equity has decreased by 39% QoQ but it has increased by 39% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.